DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years Subgroup analysis from Phase 3 AURIGA study show higher rates of MRD-negative conversion in patient populations disproportionately
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. CS5001 is well tolerated in heavily pre-trea
STEERING THE CONVERSATION: MILLENNIALS AND GEN ZS MAKE THE MOST FRIENDSHIPS ON THE BUS
Three in 10 (30%) Brits have made long-lasting friendships with people they have met on the bus Contrary to popular belief, it’s the younger generations who are nattering on the bus the most with half (46%) of Gen Z having made friends in this way 82% of Brits feel public transport plays an
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metaboli
SYM Investors Have Opportunity to Lead Symbotic Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, Dec. 8, 2024 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Symbotic Inc. (NASDAQ: SYM) between February 8, 2024 and November 26, 2024, both dates inclusive (the “Class Per
Media Advisory – Deputy Prime Minister’s itinerary for Monday, December 9, 2024
OTTAWA, ON, Dec. 8, 2024 /CNW/ – Note: All times local. Ottawa, Ontario Private meetings. 3:30 p.m. The Deputy Prime Minister will appear before the House of Commons Standing Committee on Industry and Technology. She will be joined by the Minister of Innovation, Science and Industry, Franço
Media Advisory – Prime Minister’s itinerary for Monday, December 9, 2024
OTTAWA, ON, Dec. 8, 2024 /CNW/ – Halifax Regional Municipality, Nova Scotia The Prime Minister will meet with the Premier of Nova Scotia, Tim Houston. He will be joined by the Minister of Housing, Infrastructure and Communities, Sean Fraser. Note for media: Pooled photo opportunity at the begi
AEHR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Aehr Test Systems, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Dec. 8, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Aehr Test Systems, Inc. (“Aehr” or “the Company”) (NASDAQ:
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys–CLL is one of the most common leukemias among adults affecting more than 200,000 people in the U.S.1,2 NO
SK Life Science, Inc. Presents XCOPRI® (cenobamate tablets) CV Data at the AES 2024 Annual Meeting Showing a Deeper Understanding of Cenobamate’s Dual Mechanism of Action
PARAMUS, N.J., Dec. 8, 2024 /PRNewswire/ — SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., presented data at the American Epilepsy Society (AES) Annual Meeting, showcasing its antiseizure medic
